| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/31/2000 | EP1003763A1 83 human secreted proteins |
| 05/31/2000 | EP1003751A1 Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors |
| 05/31/2000 | EP1003748A2 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| 05/31/2000 | EP1003745A1 Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation |
| 05/31/2000 | EP1003744A1 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
| 05/31/2000 | EP1003740A2 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagoists |
| 05/31/2000 | EP1003739A2 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives |
| 05/31/2000 | EP1003738A1 Bicyclic compounds as ligands for 5-ht1 receptors |
| 05/31/2000 | EP1003723A1 2-acylaminopropanamines as tachykinin receptor antagonists |
| 05/31/2000 | EP1003721A1 Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases |
| 05/31/2000 | EP1003713A1 Anthranilic acid analogs |
| 05/31/2000 | EP1003712A1 Anthranilic acid analogs |
| 05/31/2000 | EP1003544A1 C1q AND COLLECTIN RECEPTOR |
| 05/31/2000 | EP1003542A1 Use of substances having oxytocin activity for preparation of medicaments for wound healing |
| 05/31/2000 | EP1003540A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 05/31/2000 | EP1003514A1 Cyclic amine modulators of chemokine receptor activity |
| 05/31/2000 | EP1003509A1 Il-8 receptor antagonists |
| 05/31/2000 | EP1003507A1 Combination therapy comprising amlodipine and a statin compound |
| 05/31/2000 | EP1003506A1 Method of treating isolated systolic hypertension |
| 05/31/2000 | EP1003504A2 Indole derivatives and their use as mcp-1 antagonists |
| 05/31/2000 | EP1003503A1 Therapeutic combinations comprising amlodipin and atorvastatin |
| 05/31/2000 | EP1003501A1 Means of ascertaining an individual's risk profile for atherosclerotic disease |
| 05/31/2000 | EP1003500A1 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
| 05/31/2000 | EP1003497A1 Il-8 receptor antagonists |
| 05/31/2000 | EP1003491A1 Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases |
| 05/31/2000 | EP1003479A1 Method and compositions for treating late phase allergic reactions and inflammatory diseases |
| 05/31/2000 | EP1003374A4 Inhibitors of farnesyl-protein transferase |
| 05/31/2000 | EP1003374A1 Inhibitors of farnesyl-protein transferase |
| 05/31/2000 | EP1003370A1 Method of enhancing magnesium absorption and prevention of atherosclerosis |
| 05/31/2000 | EP1003365A1 Atrial natriuretic factor mutants and ischemic stroke |
| 05/31/2000 | EP0865428B1 Vitamin d analogues |
| 05/31/2000 | EP0794942B1 Substituted biphenyl compounds for the treatment of inflammation |
| 05/31/2000 | EP0721459B1 Novel oligosaccharide-containing 14-aminosteroid compounds and novel diastereoselective aminosteroid process chemistry |
| 05/31/2000 | EP0697011B1 Large potassium bicarbonate crystals and process for the preparation thereof |
| 05/31/2000 | EP0646005B1 Use of an imidazole for the preparation of a medicament for the treatment of arteriosclerosis |
| 05/31/2000 | EP0627921B1 Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof |
| 05/31/2000 | DE19856475A1 Nichtsteroidale Entzündungshemmer Nonsteroidal anti-inflammatory drugs |
| 05/31/2000 | CN1255142A B-ring estratriene diol sulphates |
| 05/31/2000 | CN1255133A 1,5-dihydro-pyrazolo [3,4-D]-pyrimidinone derivatives |
| 05/31/2000 | CN1255131A Amidine derivatives as inhibitors of nitric oxide synthase |
| 05/31/2000 | CN1255130A Compounds |
| 05/31/2000 | CN1254597A Antiswelling medicine |
| 05/31/2000 | CN1052978C Process for the preparation of alpha-tocopherol |
| 05/31/2000 | CN1052976C Substituted benzenesulfonylureas and -thioureas, preparation process and possible uses of pharmaceutical preparation therefor |
| 05/30/2000 | US6069175 Administering to a mammal in need a therapeutically effective amount of a member selected from the 4-hydroxy tamoxifen, raloxifene, toremifene, centchroman, idoxifene to treat atherosclerosis |
| 05/30/2000 | US6069162 Indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production |
| 05/30/2000 | US6069158 10,11-dihydro-3(3-(4-amino-2-pyridylamino)-1-propyloxy)-5h-dib enzo(a,d)cycloheptene-10-acetic acid |
| 05/30/2000 | US6069156 Indole derivatives as cGMP-PDE inhibitors |
| 05/30/2000 | US6069152 Nervous system disorders; cardiovascular disorders; gastrointestinal disorders |
| 05/30/2000 | US6069148 Cycloalkano-pyridines |
| 05/30/2000 | US6069143 Anticoagulants |
| 05/30/2000 | US6069139 Method and composition for prophulaxis and treatment of retinal diseases |
| 05/30/2000 | US6069135 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents |
| 05/30/2000 | US6069130 Prodrugs useful in vivo or invitro for preventing or treating coagulation disorders |
| 05/30/2000 | US6069129 Elastin derived composition and method of using same |
| 05/30/2000 | US6069006 Connective tissue growth factor (CTGF) regulatory nucleic acid sequences |
| 05/30/2000 | US6068999 Dietary supplement for supporting cerebrovascular tone and treating migraine headaches |
| 05/30/2000 | US6068845 Inhibitory activity on the abnormal production of extracellular matrices in dermal fibroblasts activated with tranforming growth factor beta by administering the plant extract of a plant belonging to the genus sophora |
| 05/30/2000 | CA2171844C Sustained release formulations for 24 hour release of metoprolol |
| 05/30/2000 | CA2120045C Use of hyaluronic acid and forms to prevent arterial restenosis |
| 05/30/2000 | CA2004747C Substituted phenylpyrimidines useful in the treatment of cns disorders |
| 05/25/2000 | WO2000029620A1 Methods of facilitating vascular growth |
| 05/25/2000 | WO2000029601A1 A method for depopulating of vertebrate testis and for generation of transgenic species |
| 05/25/2000 | WO2000029584A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 05/25/2000 | WO2000029583A2 Immunoglobulin superfamily proteins |
| 05/25/2000 | WO2000029501A1 Radioactive coating solutions, methods, and substrates |
| 05/25/2000 | WO2000029447A1 Rhamm antagonist antibodies |
| 05/25/2000 | WO2000029446A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies |
| 05/25/2000 | WO2000029435A1 12 human secreted proteins |
| 05/25/2000 | WO2000029422A1 31 human secreted proteins |
| 05/25/2000 | WO2000029405A1 Method for preparing (2s)-1-[ (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide |
| 05/25/2000 | WO2000029401A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/25/2000 | WO2000029384A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| 05/25/2000 | WO2000029381A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 05/25/2000 | WO2000029379A1 1-aminoethylquinoline derivatives for treating urinary incontinence |
| 05/25/2000 | WO2000029015A2 INFLUENCING OF ANGIGENESIS USING CD66a |
| 05/25/2000 | WO2000029003A2 Method for preventing and reversing atherosclerosis in mammals |
| 05/25/2000 | WO2000028983A1 Novel 4-dedimethy laminotetra cycline derivatives |
| 05/25/2000 | WO2000028981A2 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 05/25/2000 | WO2000028920A1 Therapeutic use of polymers |
| 05/25/2000 | WO2000016797A3 Use of glp-1 or analogs in treatment of stroke |
| 05/25/2000 | WO2000012111A3 Selective treatment of endothelial somatostatin receptors |
| 05/25/2000 | WO2000012049A3 A method for the treatment of staphylococcal disease |
| 05/25/2000 | WO2000002576A9 Egf-genistein for prevention of restenosis |
| 05/25/2000 | DE19853278A1 New 4-amino-2-aryl-cyclopentapyrimidine derivatives are activators of soluble guanylate cyclase, useful for treating or preventing e.g. thrombosis and restenosis |
| 05/25/2000 | DE19850986A1 Die gentechnische Prägung von Zellen und ihre Verwendung zur Prophylaxe und Therapie von Erkrankungen The genetic imprint of cells and their use in the prophylaxis and treatment of diseases |
| 05/25/2000 | CA2351585A1 Influencing of angigenesis using cd66a |
| 05/25/2000 | CA2350785A1 31 human secreted proteins |
| 05/25/2000 | CA2350443A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 05/25/2000 | CA2350420A1 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 05/25/2000 | CA2350391A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies |
| 05/25/2000 | CA2348824A1 12 human secreted proteins |
| 05/25/2000 | CA2348676A1 Method for preparing (2s)-1-¬ (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl| pyrrolidine-2- carboxamide |
| 05/25/2000 | CA2348599A1 Method for preventing and reversing atherosclerosis in mammals |
| 05/25/2000 | CA2348459A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/25/2000 | CA2347833A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 05/25/2000 | CA2340468A1 Methods of facilitating vascular growth |
| 05/24/2000 | EP1002802A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1002797A1 4,5-DIHYDRO- 1H]-BENZ g]INDAZOLE-3-CARBOXYLIC ACID DERIVATIVES |
| 05/24/2000 | EP1002544A1 Anti-edema agent |